Summary
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine (MDHMA), also known as FLEA, falls within the realm of entactogenic, psychedelic, and stimulant compounds, classifying it under the phenethylamine and amphetamine chemical categories. This chemical entity serves as the N-hydroxy homolog of MDMA, commonly referred to as “Ecstasy,” and the N-methyl homolog of MDOH. Alexander Shulgin carried out the pioneering work on MDHMA.
Within the pages of his book, “PiHKAL” (Phenethylamines I Have Known And Loved), Shulgin documented the recommended dosage range for MDHMA, which typically spans from 100 to 160 milligrams. The effects of MDHMA are anticipated to persist for a duration of around 4 to 8 hours.
Shulgin’s description of MDHMA portrays it as a substance capable of inducing entactogenic sensations and open-hearted effects reminiscent of MDMA. It tends to facilitate enhanced communication and an augmented appreciation of the senses.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 214414-88-7 |
|---|---|
| ChemSpider | 21106310 |
| UNII | E2816HU3KT |
| CompTox Dashboard (EPA) | DTXSID90658377 |
| Chemical and physical data | |
| Formula | C11H15NO3 |
| Molar mass | 209.245 g·mol−1 |
Legality
In the United Kingdom, this compound is categorized as a Class A drug under the regulations outlined in the Misuse of Drugs Act.
FAQ
- What is MDHMA?
- MDHMA, short for 3,4-methylenedioxy-N-hydroxy-N-methylamphetamine, is a chemical compound known for its properties as an entactogen, psychedelic, and stimulant. It belongs to the phenethylamine and amphetamine chemical classes.
- How does MDHMA compare to MDMA and MDOH?
- MDHMA is the N-hydroxy homolog of MDMA, also called “Ecstasy,” and the N-methyl homolog of MDOH. While these compounds share structural similarities, they may exhibit distinct effects and characteristics.
- Who was responsible for the synthesis and assessment of MDHMA?
- Alexander Shulgin, a notable figure in the field of psychopharmacology, was responsible for the initial synthesis and evaluation of MDHMA.
- What is the recommended dosage range for MDHMA?
- According to Alexander Shulgin’s documentation in “PiHKAL” (Phenethylamines I Have Known And Loved), the suggested dosage range for MDHMA typically falls within 100 to 160 milligrams.
- How long do the effects of MDHMA typically last?
- The effects of MDHMA are expected to endure for approximately 4 to 8 hours, providing users with an extended psychedelic experience.
- What kind of effects does MDHMA produce?
- MDHMA is renowned for its entactogenic qualities, often eliciting open-hearted and empathetic effects akin to MDMA. Users may experience improved communication and heightened sensory appreciation.
- Do drug laws in the United Kingdom regulate MDHMA?
- Yes, MDHMA is classified as a Class A drug under the Misuse of Drugs Act in the United Kingdom, indicating that its possession, distribution, and use are subject to strict legal controls.
- Is MDHMA considered safe for consumption?
- The safety of using MDHMA is not well-documented, and it is not approved for any medical or therapeutic purposes. As with all psychoactive substances, there are potential risks associated with its use, and caution is advised.
- Are there harm reduction measures for MDHMA use?
- Engaging in harm reduction practices, such as using substance testing services and starting with lower doses, can help minimize risks associated with MDHMA use. However, the safest approach is to abstain from using such substances altogether.
References
- Shulgin A, Shulgin A (September 1991). “PiHKAL: A Chemical Love Story.” This engaging work authored by Alexander Shulgin and Ann Shulgin, published by Transform Press, provides a captivating exploration of their experiences with psychedelic compounds and the chemistry behind them. It remains a widely recognized resource in the field of psychopharmacology.
- “UK Misuse of Drugs Act 2001 Amendment Summary.” Isomer Design. This document offers a comprehensive summary of the amendments introduced in the UK Misuse of Drugs Act in 2001. It outlines the legal changes related to controlled substances in the United Kingdom and serves as a valuable reference for understanding drug regulations in the country.